H-10 · Standards Field: IHPSO Health Standards
Hormonal & Reproductive Health Communication
Requirements for scope-appropriate, evidence-proportionate and risk-aware communication involving hormonal and reproductive health.
Purpose
Hormonal and reproductive health involves complex biological processes, symptoms, life stages, laboratory data and clinical questions. Terms such as “hormone balance,” “cortisol problem,” “testosterone optimization,” “estrogen dominance,” “fertility optimization” or “menopause support” are often used broadly across health, coaching, wellness and biohacking. H-10 establishes a shared IHPSO standard for evidence-proportionate, transparent and scope-appropriate communication. It is intended particularly to prevent nonspecific symptoms from being attributed to hormonal disorders without sufficient basis, individual laboratory values from being diagnostically overinterpreted, or coaching, supplement and lifestyle services from being presented as substitutes for necessary medical or reproductive-health assessment.
Scope
H-10 applies to hormone-related claims, menstruation and cycle topics, menopause and perimenopause, fertility and reproductive-health claims, testosterone, estrogen, progesterone, cortisol and related statements, biomarkers, supplements, lifestyle interventions and consumer tracking. It covers scope, evidence, claims, laboratory data, uncertainty, safety, referral, sensitive communication and interfaces with nutrition, sleep, stress and longevity. H-10 does not define hormonal or reproductive diagnoses, a universal “optimal” hormone concentration, fertility prognosis or medical hormone or fertility treatment. Diagnosis, prescribing, hormone replacement therapy, fertility treatment and other regulated clinical activities may be subject to specific qualification and legal requirements.
Requirements
- Communication must not imply diagnostic or therapeutic authority beyond the Professional's actual role and scope.
- General education and lifestyle support must be distinguished from medical interpretation, diagnosis, prescribing and treatment.
- Nonspecific symptoms must not automatically be attributed to a specific hormonal disorder. Symptom pattern ≠ hormone diagnosis.
- Labels such as “hormone imbalance,” “estrogen dominance” or “high cortisol” must not be used as diagnoses unless definition, evidence, measurement basis and scope support the claim.
- “Adrenal fatigue” must not be presented as an established medical diagnosis or as a validated medical explanation for nonspecific symptoms. It must be distinguished from adrenal insufficiency, a recognized medical condition whose diagnosis and treatment require appropriately qualified clinical care.
- A single hormone or biomarker value is not automatically a diagnosis, cause or treatment indication; H-02 also applies.
- A single low testosterone result is not automatically a diagnosis of hypogonadism. Diagnosis, evaluation of cause and treatment decisions require appropriate clinical assessment under the relevant professional and legal requirements.
- Timing, circadian rhythm, cycle phase, life stage, medications, hormonal contraception, pregnancy, acute stress, illness, measurement method and other contextual factors may influence hormone measurements.
- Population reference interval ≠ individual target.
- Consumer tests, at-home tests, wearables, cycle apps and algorithmic fertility/hormone scores are not clinically validated diagnoses or prognoses solely because of technical precision; H-03 applies accordingly.
- For consumer and at-home tests, Analytical Validity, Clinical Validity and Clinical Utility must be distinguished. A technically reliable measurement does not automatically establish diagnostic meaning or clinical benefit from actions based on that result.
- Cycle data may be useful for education and tracking but do not alone establish ovulation, fertility, hormonal disease or symptom cause.
- Menstruation tracking, fertile-window estimation, evidence of ovulation and fertility prognosis are distinct levels of inference and must not be treated as equivalent without adequate validation.
- Fertility-related claims require particular caution; lifestyle, supplement, tracking or coaching approaches must not guarantee pregnancy or conception without sufficient evidence.
- Fertility, fecundability, ovarian reserve, ovulation, pregnancy probability and reproductive ageing are distinct concepts.
- Ovarian reserve ≠ fertility. AMH, AFC or other ovarian-reserve markers may provide relevant information in appropriate clinical contexts, but must not be presented alone as direct measures of egg quality, natural conception probability or an individual reproductive lifespan.
- Age can materially affect reproductive probability, but population-level age effects do not determine an individual outcome with certainty. Population risk ≠ individual certainty.
- Pregnancy, clinical pregnancy and live birth are distinct outcomes and must not be treated as interchangeable in fertility claims without sufficient basis.
- Menopause and perimenopause may be explained educationally, but individual symptoms must not be diagnostically attributed outside scope.
- Hormone-related claims must comply with H-01 and U-03.
- “Hormone balance” is not, by itself, a sufficiently precise clinical or scientific outcome and should not be used as a self-explanatory health claim without further definition. Claims should identify the hormone, population, measurement context and relevant outcome concerned.
- Lifestyle interventions must not automatically be presented as normalizing a hormone or treating a hormonal disorder.
- “Hormone optimization” requires a defined, relevant outcome. Moving a hormone value toward a preferred numerical range is not by itself evidence of health benefit.
- Supplements marketed for hormones, menopause or fertility must comply with H-04; product categories prove neither efficacy nor individual appropriateness.
- Prescription hormones, fertility drugs or other regulated medicines must not be recommended, altered, discontinued or dosed outside legal and professional authority.
- Fertility goals may be clinically relevant to hormone-related treatment or intervention decisions. Professionals outside the relevant scope must not independently alter treatment on that basis and should refer appropriately.
- Lifestyle or supplement recommendations must not delay or alter necessary medical assessment, treatment or prescribed medication without qualified evaluation.
- New, unusual, severe or persistent symptoms must not be dismissed as necessary “detox,” “hormone reset” or “cycle reset.” Red flag ≠ diagnosis.
- Possible pregnancy, pregnancy, postpartum period, breastfeeding and fertility treatment may materially change the risk and scope of other interventions.
- Reproductive-health communication must respect autonomy, privacy and voluntary decision-making and must not influence decisions through pressure, shame or unsupported fear-based claims.
- Communication about weight, menstruation, fertility, menopause, sexual function or hormones should be factual and non-stigmatizing and must not unnecessarily pathologize biological variation.
- Where Nutrition/Energy Availability is relevant, H-05 applies; where Sleep/Stress is relevant, H-06 and H-09 apply; associations do not automatically establish a single hormonal cause.
- Longevity/anti-aging claims involving hormonal interventions must consider H-11; a changed hormone value does not prove extended lifespan or improved healthspan.
- New or insufficiently validated tests, scores or interventions must communicate evidence gaps transparently; H-12 applies where relevant.
- Diagnosis, fertility prognosis, medication management, pregnancy complications, substantial bleeding or pain symptoms and other clinically relevant questions require scope awareness and referral where appropriate.
- Where acute danger may be present, IHPSO Referral Levels and local emergency procedures apply; H-10 is not medical or reproductive-health triage.
- Evidence Classification is claim-specific and must not be assigned broadly to a hormone, test or intervention.
Evidence classification
Not assigned at standard level
Justification
H-10 covers different hormones, reproductive life stages, tests, interventions, populations and outcomes with substantially different evidence and regulatory contexts. A single Evidence Classification would therefore be methodologically inappropriate. Under the IHPSO Health Standards Architecture 1.0, Evidence Classification is used only where scientifically applicable and on a claim-specific basis.